BioCryst Pharmaceuticals BCRX Inventory write-downs
Inventory write-downs at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InventoryWriteDown.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's inventory write-downs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's inventory write-downs?
- BioCryst Pharmaceuticals (BCRX) reported inventory write-downs of $74K in Q1 2026.
- How has BioCryst Pharmaceuticals's inventory write-downs changed year-over-year?
- BioCryst Pharmaceuticals's inventory write-downs decreased by 64.6% year-over-year, from $209K to $74K.
- What does inventory write-downs mean?
- Represents the non-cash charge taken to reduce the carrying value of inventory when its market value falls below cost or it becomes obsolete. This metric signals potential issues with product demand, supply chain management, or inventory quality control. High levels of write-downs can indicate inefficient inventory management or a decline in the commercial viability of specific product lines.